Eliot Forster, F-star Therapeutics CEO
CFIUS review triggers delay on F-star's sale to Chinese player
For F-star, the once high-flying UK biotech helmed by Eliot Forster, the $161 million all-cash acquisition by China’s Sino Biopharm was a last resort as …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.